Empliciti sales estimate: $89M (consensus: $101M) in Q2 2021 to BMS; Empliciti sales projection: $366M (consensus: $390M) in 2021 to BMS (Barclays) - Jul 19, 2021 - A subscription to REFINITIV is required to access document 92933255 | Page no: 12 | REPORT TITLE: "U.S. biopharmaceuticals: 2Q21 earnings preview" | AUTHOR: Carter Gould, et al | DATE: 07/06/21
Sales • Sales projection • Hematological Malignancies • Multiple Myeloma • Oncology
|
|
If you have access to Aftermarket Research from Refinitiv, please log in to your account using this link and enter report number or title to find the report. If you don’t have access but would like to purchase the report please contact OnDemand@refinitiv.com.
|